Literature DB >> 3407

Pharmacokinetics of digoxin in the rat.

L I Harrison, M Gibaldi.   

Abstract

Previous studies on the pharmacokinetics of 3H-digoxin in the rat have been based on total radioactivity in the plasma, even though the drug is extensively metabolized in this species. A comparison of total radioactivity vs. unchanged drug in rat plasma after administration of 3H-digoxin clearly showed the need to separate digoxin from its metabolites. The pharmacokinetics of digoxin were therefore examined using solvent extraction and thin-layer chromatography to isolate unchanged drug. Digoxin levels after a 1 mg/kg iv dose were measured in the plasma and urine of adult male rats in which the bile duct or the ureters had been ligated, as well as in sham-operated controls. In all cases, digoxin concentrations were best described by a two-compartment open model. Digoxin was rapidly eliminated from the plasma of controls, with a half-life of 2.5 hr, a volume of distribution of 3.6 liter/kg, and a renal clearance somewhat lower than the glomerular filtration rate. No significant change in these parameters was observed in rats with bile duct ligation. The total body clearance of 5.77 ml/min in the controls was reduced by only 10% in the bile duct-ligated rats. In animals with bilateral ureter ligation, the body clearance was reduced by 30% and the plasma half-life of digoxin was increased to 4 hr, although no significant change in the apparent volume of distribution was noted. Approximately 60% of the total body clearance was unaffected by bile duct and ureter ligations, and was assumed to be due to biotransformation. Biliary excretion was found to be important for digoxigenin bisdigitoxoside, inasmuch as rats with bile duct ligation showed elevated metabolite levels in the plasma as well as a 3-fold increase in renal excretion of the bisglycoside.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 3407

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

1.  Significance of binding to Na,K-ATPase in the tissue distribution of ouabain in guinea pigs.

Authors:  H Harashima; M Mamiya; M Yamazaki; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

2.  Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha.

Authors:  Makrem Ben Reguiga; Laurence Bonhomme-Faivre; Simone Orbach-Arbouys; Robert Farinotti
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

3.  Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Authors:  Ken-ichi Umehara; Gian Camenisch
Journal:  Pharm Res       Date:  2011-10-20       Impact factor: 4.200

Review 4.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

5.  Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.

Authors:  Kerry B Goralski; Georgy Hartmann; Micheline Piquette-Miller; Kenneth W Renton
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Pharmacokinetics of digoxin in the turkey and comparison with other species.

Authors:  E Park; S Einzig; N A Staley; G R Noren
Journal:  J Pharmacokinet Biopharm       Date:  1981-06

7.  The Effects of Pregnenolone 16α-Carbonitrile Dosing on Digoxin Pharmacokinetics and Intestinal Absorption in the Rat.

Authors:  Simon Lowes; Iain S Haslam; Britt-Marie Fihn; Constanze Hilgendorf; Johan E Karlsson; Nicholas L Simmons; Anna-Lena Ungell
Journal:  Pharmaceutics       Date:  2010-03-15       Impact factor: 6.321

8.  Digoxin absorption decreased independently of P-gp activity in rats with irinotecan-induced gastrointestinal damage.

Authors:  Toshiaki Tsuchitani; Takeshi Akiyoshi; Ayuko Imaoka; Hisakazu Ohtani
Journal:  J Pharm Health Care Sci       Date:  2021-07-01

Review 9.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

Review 10.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.